Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07449234) titled 'A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis' on Feb. 27.

Study Type: Observational

Primary Sponsor: Janssen-Cilag Ltd.

Condition: Psoriasis

Recruitment Status: Recruiting

Date of First Enrollment: February 9, 2026

Target Sample Size: 200

Countries of Recruitment: Austria

To know more, visit https://clinicaltrials.gov/study/NCT07449234

Published by HT Digital Content Services with permission from Health Daily Digest....